Key facts
- SHINE Technologies received EU CMA for Ilumira Lu-177.
- The authorization comes from the European Medicines Agency (EMA).
- Ilumira Lu-177 is a radioisotope used in targeted radiopharmaceutical therapies.
- The CMA permits production and supply for clinical trials in the EU.
The European Medicines Agency (EMA) authorization for SHINE Technologies' Ilumira Lu-177 radioisotope is a significant step in the development of targeted radiopharmaceutical therapies. This approval allows SHINE to supply the crucial radioisotope for clinical trials within the EU, potentially accelerating the availability of new cancer treatments that use radiation to target and destroy cancer cells.